Board of Directors
Anna Malm Bernsten
Born: 1961. Title: Chairman of the Board. Member of the Board since 2006. Chairman of the Remuneration Committee and Member of the Audit Committee and the R&D Committee.
Education: M.Sc. in Engineering.
Background: M.Sc. in Engineering with an extensive knowledge of the life sciences sector. Runs own consultancy firm operating in the fields of leadership strategy and business development. Experience of senior positions with, amongst others, GE Healthcare Life Sciences, Pharmacia, Assa Abloy, Medivir and Baxter Medical. Former President & CEO of Carmeda AB.
Other directorships: Chairman of the Board of Björn Axén. Member of the Boards of Cellavision, Pågengruppen and Probi.
Shares in Medivir: 3,724 class B shares.
Born: 1954. Title: Member of the Board since 2014. Member of the R&D Committee and the Audit Committee.
Education: Doctor of Medicine and Associate Professor in physiology at the Karolinska Institute.
Background: Physician (board certified in anaesthesia and intensive care), dentist.
Other directorships: Chairman of the Boards of the Karolinska University Hospital and TFS International AB, Member of the Boards of the Swedish Research Council, SwedenBio, AnaMar AB, Infant Bacterial Therapeutics AB, Mereo Biopharma Ltd, Alligator Biosciences and a senior advisor to Phase4 Partners, UK.
Shares in Medivir: 1,345 class B shares.
Anders R Hallberg
Born: 1945. Title: Member of the Board since 2012. Chairman of the R&D Committee.
Education: Professor of Medicinal Chemistry at Uppsala University, Faculty of Pharmacy.
Background: Held a number of positions as a scientific advisor at Astra Zeneca and smaller pharmaceutical companies between 1990 and 2006. Prior to this, he was the Head of the Medicinal Chemistry Department at Astra in Lund. Vice-Chancellor (Rector) of Uppsala University between 2006 and 2011. He has published over 270 scientific articles, and is co-author of a large number of granted patents. Member of the Royal Swedish Academy of Sciences, and the Royal Swedish Academy of Engineering Sciences. Awarded honorary doctorates in Sweden and other countries.
Other directorships: Member of Boards of Foundations and Universities.
Shares in Medivir: 2,500 class B shares.
Born:1953. Title: Member of the Board since 2017. Member of the R&D Committee.
Education: M. Sc. Pharmacy. Has worked in the pharmaceutical industry since 1978.
Background: CEO of Linc AB, which invests in life sciences. Since 1990, primarily active as an investor in and a Member of the Boards of pharmaceutical development companies. Experience of developing and commercialising products.
Other directorships: Member of the Boards of Linc AB, Livland Skog AB, Calliditas Therapeutics AB, Proequo AB, Sedana Medical AB, Stille AB and Swevet AB, and a number of smaller companies.
Shares in Medivir: 958,283 class B shares (through company).
Born: 1957. Title: Member of the Board since 2015. Member of the Remuneration Committee and Chairman of the Audit Committee.
Education: B.Sc. in Economics and Business Administration from the Stockholm School of Economics.
Background: Extensive experience of the financial and equity markets and of corporate governance issues. Previous employed by Neonet, Odin Förvaltning, Nordea Asset Management and SEB Asset Management, amongst others.
Other directorships: Founder and now Chairman of the Board of Nordic Investor Services AB. Member of the Boards of Concordia Maritime AB, Recipharm AB and Stendörren Fastigheter.
Shares in Medivir, including family: 5,250 class B shares.
Born: 1945. Title: Member of the Board since 2017. Member of the R&D Committee.
Education: Professor of Tumour Biology at Uppsala University, the Faculty of Medicine, since 1986.
Background: Dean of the Faculty of Medicine at Uppsala University, 1996-2002, and Vice-Rector of Medicine and Pharmacy, 1999-2002. Chairman of the research board of the Swedish Cancer Society, 2003-2013. He has published over 300 papers in scientific journals, primarily on the mechanisms governing the uncontrolled growth of cancer cells. Member of the Royal Swedish Academy of Sciences, the European Molecular Biology Organisation, and the European Academy of Cancer Sciences. He has received a number of prizes and awards for his research and has been cited over 25,000 times by other researchers.
Other directorships: Member of the Board of Hamlet Pharma AB and several advisory groups for medical research financing.
Shares in Medivir: 2,000 class B shares.
Born: 1952. Title: Member of the Board. Employee representative, appointed by The Swedish Association of Graduate Engineers, since 2017. Employed as Distinguished Scientist, Medicinal Chemistry Department.
Background: Assoc. Professor at the Dept. of Organic Chemistry, University of Stockholm.
Shares in Medivir: 17,417 class B shares.